AMENDMENT 1

STOPSTORM CONSORTIUM AGREEMENT

STOPSTORM: A PROSPECTIVE EUROPEAN VALIDATION COHORT FOR STEREOTACTIC THERAPY OF RE-ENTRANT TACHYCARDIA



STORM.eu

Grant Agreement no.: 945119

Call/Topic identifier: H2020-SC1-BHC-08-2020-RTD-RIA

Amendment to CONSORTIUM AGREEMENT

BETWEEN:

1. CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL (CAU), established in OLSHAUSENSTRASSE 40, KIEL 24118, Germany, with **Universitätsklinikum Schleswig-Holstein (UKSH)** as Third Party to Christian-Albrechts-Universität zu Kiel as set out in the Grant Agreement. The (new) Coordinator

2. **FAKULTNI NEMOCNICE OSTRAVA (FNO)**, established in 17 LISTOPADU 1790, OSTRAVA PORUBA 708 52, Czech Republic, VAT number: CZ00843989,

3. **Institut klinické a experimentální medicíny (IKEM)**, established in Videnska 1958/9, PRAGUE 4 14021, Czech Republic, VAT number: CZ00023001,

4. **NEMOCNICE AGEL TRINEC PODLESI AS (NPO)**, established in KONSKA 453, TRINEC 739 61, Czech Republic, VAT number: CZ48401129,

5. **UNIVERSITAIR MEDISCH CENTRUM UTRECHT (UMCU)**, established in HEIDELBERGLAAN 100, UTRECHT 3584 CX, Netherlands, VAT number: NL004205315B01

6. **RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG (UHEI)**, established in SEMINARSTRASSE 2, HEIDELBERG 69117, Germany, VAT number: DE811225433,

7. **CHARITE - UNIVERSITAETSMEDIZIN BERLIN (CHARITE)**, established in Chariteplatz 1, BERLIN 10117, Germany, VAT number: DE228847810,

8. **TECHNISCHE UNIVERSITAET DRESDEN (TUD)**, established in HELMHOLTZSTRASSE 10, DRESDEN 01069, Germany, VAT number: DE188369991,

9. **UNIVERSITAET zu LUEBECK (UZL)**, established in RATZEBURGER ALLEE 160, LUBECK 23538, Germany, VAT number: DE202095138,

~~10. **HERZZENTRUM LEIPZIG GMBH (ULEIHC)**, established in STRUEMPELLSTRASSE 39, LEIPZIG 04289, Germany, VAT number: DE161952414,~~ (termination of participation as of 2023/12/14)

11. **CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)**, established in RUE DU BUGNON 21, LAUSANNE 1011, Switzerland, VAT number: CHE108.910.225,

12. **Insel Gruppe AG (BERN)**, established in FREIBURGSTRASSE 18, BERN 3010, Switzerland, VAT number: CHE433951246MWST,

13. **UNIVERSITAT ZURICH (USZ)**, established in RAMISTRASSE 71, ZURICH 8006, Switzerland, VAT number: CH233525,

14. **Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy (NRIO)**, established in UL. W K ROENTGENA 5, WARSZAWA 02781, Poland, VAT number: PL5250008057,

15. **GORNOSLASKIE CENTRUM MEDYCZNE IM. PROF. LESZKA GIECA SLASKIEGO UNIWERSYTETU MEDYCZNEGO W KATOWICACH (GCM)**, established in UL ZIOLOWA 45-47, KATOWICE 40 635, Poland, VAT number: PL9542269625,

16. **AARHUS UNIVERSITET (AU)**, established in NORDRE RINGGADE 1, AARHUS C 8000, Denmark, VAT number: DK31119103,

17. **AARHUS UNIVERSITETSHOSPITAL (AUH)**, established in PALLE JUUL-JENSENS BOULEVARD 99, AARHUS 8200, Denmark, VAT number: DK29762929,

18. **CONSORCIO MAR PARC DE SALUT DE BARCELONA (IMIM)**, established in PASEO MARITIM 25-29, BARCELONA 08003, Spain, VAT number: ESS0800471E,

19. **SERVICIO MADRILENO DE SALUD (SERMAS)**, established in PLAZA CARLOS TRIAS BERTRAN 7, MADRID 28020, Spain, VAT number: ESQ2801221I,

20. **FUNDACION INVESTIGACIÓN HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA (FIHGUV)**, established in AV TRES CRUCES 2, VALENCIA 46014, Spain, VAT number: ESG96792221,

21. **AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA (AUSL RE)**, established in VIA AMENDOLA 2, REGGIO EMILIA 42122, Italy, VAT number: IT01598570354,

22. **FONDAZIONE CENTRO NAZIONALE DI ADROTERAPIA ONCOLOGICA (CNAO)**, established in STRADA CAMPEGGI 53, PAVIA PV 27100, Italy, VAT number: IT03491780965,

23. **ISTITUTO DON CALABRIA (IRCCSDC)**, established in VIA SAN ZENO IN MONTE 23, VERONA 37129, Italy, VAT number: IT00280090234,

24. **UNIVERSITA DEGLI STUDI DI TORINO (UNITO)**, established in VIA GIUSEPPE VERDI 8, TORINO 10124, Italy, VAT number: IT02099550010, represented by the Director of the Department of Medical Sciences Prof. Anna Sapino,

25. **FONDAZIONE IRCCS POLICLINICO SAN MATTEO (IRCCS OSM)**, established in VIALE GOLGI 19, PAVIA 27100, Italy, VAT number: IT00580590180,

26. **UNIVERSITEIT MAASTRICHT (UM)**, established in Minderbroedersberg 4-6, MAASTRICHT 6200 MD, Netherlands,

27. **ACADEMISCH ZIEKENHUIS LEIDEN (LUMC)**, established in ALBINUSDREEF 2, LEIDEN 2333 ZA, Netherlands, VAT number: NL003566213B01,

28. **STICHTING AMSTERDAM UMC (AUMC)**, established in DE BOELELAAN 1117, 1081 HV, AMSTERDAM, Netherlands, VAT number: NL855546670B01.

29. **STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC (MAASTRO)**, established in Dr. Tanslaan 12, MAASTRICHT 6229 ET, Netherlands, VAT number: NL004210104B01,

30. ~~**STICHTING CATHARINA ZIEKENHUIS (SCZ)**, established in MICHELANGELOLAAN 2, EINDHOVEN 5623EJ, Netherlands, VAT number: NL002655135B01,~~ (termination of participation as of 2023/12/14)

31. **HARTERAAD (HART)**, established in PRINSES CATHARINA-AMALIASTRAAT 10, SGRAVENHAGE 2496 XD, Netherlands,

hereinafter , jointly or individually, referred to as “Beneficiaries” or “Beneficiary”

relating to the Action entitled

A PROSPECTIVE EUROPEAN VALIDATION COHORT FOR STEREOTACTIC THERAPY OF RE-ENTRANT TACHYCARDIA

in short

STOPSTORM

hereinafter referred to as “Project”

WHEREAS:

- The Beneficiaries, have agreed to a Consortium Agreement to the Project , effective as of 1 May 2021.
- The Grant Agreement was amended on 2024/04/01 and now states, amongst other changes related to Annex 1 the Description of Action (DoA) and Annex 2 that HERZZENTRUM LEIPZIG GMBH (ULEIHC), and STICHTING CATHARINA ZIEKENHUIS (SCZ) are no longer Beneficiaries. The Beneficiaries aligned on this change in a Consortium Council decision on 2023/12/14.
- Christian-Albrechts-Universität zu Kiel takes over the position of the Coordinator from Universitair Medisch Centrum Utrecht starting 2024/01/01. Universitair Medisch Centrum Utrecht remains a Beneficiary of the Project as set out in the respective Amendment to the Grant Agreement. The Beneficiaries aligned on this change in a Consortium Council decision on 2023/12/14.
- Christian-Albrechts-Universität zu Kiel will fulfil its duties as the Coordinator in close cooperation with its Universitätsklinikum Schleswig-Holstein which is a Third Party to CAU as set out in the Grant Agreement.

Due to the changes within the Project and the participating Beneficiaries, the Beneficiaries need to amend some provisions of the Consortium Agreement.

THEREFORE, IT IS HEREBY AGREED AS FOLLOWS with retroactive effect as of 2024/01/01:

1. Coordinator

CAU takes over the role of the Coordinator of the Project as set out in the Amendment AMD-945119-30 to the Grant Agreement starting 2024/01/01.

2. Beneficiary termination

The participations of the following Beneficiaries are terminated:

HERZZENTRUM LEIPZIG GMBH (ULEIHC), established in STRUEMPELLSTRASSE 39, LEIPZIG 04289, Germany, VAT number: DE161952414, (termination of participation as of 2023/12/14)

STICHTING CATHARINA ZIEKENHUIS (SCZ), established in MICHELANGELOLAAN 2, EINDHOVEN 5623EJ, Netherlands, VAT number: NL002655135B01, (termination of participation as of 2023/12/14)

This implies the following changes to the Consortium Agreement: These Beneficiaries are deleted from the recital of the Agreement.

3. Amendment of Section 6.6 and Insertion of Section 6.7 and 6.8

Section 6.6 shall be amended as follows:

An External Advisory Board (EAB) will be appointed and steered by the Management Board. The EAB shall assist and facilitate the decisions made by the Consortium Council.

Where necessary, he Coordinator will execute, as coordinator, a non-disclosure agreement for the Project (hereafter "NDA") with each member of the EAB, in order to protect Confidential Information disclosed by any of the Beneficiaries to any member of the EAB. The NDA for the EAB members is enclosed in Attachment 5 and any changes thereto need to be agreed by the Beneficiaries.

The Coordinator shall write the minutes of the EAB meetings and prepare the implementation of the EAB's suggestions. The EAB members shall be allowed to participate in Consortium Council meetings upon invitation but have not any voting rights.

The following Section 6.7 and 6.8 shall be inserted.

6.7 Observer Groups

By way of exception to Section 6.4.4 above, the Beneficiaries hereby accept the Coordinator to execute, in its role as a coordinator and where legally necessary, a non-disclosure agreement for the Project (hereafter "NDA") with Observer Groups agreed upon by the Consortium Council and as described in the Grant Agreement, DoA, Part B, Section 2.2.2 and 3.3.1 in order to protect Confidential Information disclosed by any of the Beneficiaries to any member of the Observer Groups. The NDA for Observer Groups is enclosed in Attachment 5 and any changes thereto need to be agreed by the Beneficiaries. The Coordinator will inform the Beneficiaries of any such non-disclosure-agreement.

6.8. External Registry Partners

The External Registry Partners commit to implement Project tasks as described in the DoA, Part B, Section 3.3 of the amended Grant Agreement: they will support the STOPSTORM registry with clinical data according to the STOPSTORM registry protocol. For the avoidance of doubt, the External Registry Partners do not sign or receive the Grant Agreement or the Consortium Agreement and do not receive funding from the Granting Authority and therefore do not have a right to charge costs or claim contributions from the Granting Authority. External Registry Partners must ensure their own funding for the implementation of the Project. Since External

Registry Partners do not receive funding for their support from the Granting Authority, they may request help from other Beneficiaries to fulfil their support accordingly and those Beneficiaries may in turn claim budget release as described in Section 7.3.3. of the Consortium Agreement if the subject data from the associated External Registry Partners (mandatory requirements) has been collected and checked for quality as described in the Grant Agreement, DoA, part B Section 1.3.7 (Table 1.3 and Quality Assessment and Harmonisation) and as updated by the Management Board during the Project.

To add External Registry Partners to the Project, the Coordinator will execute, in its role as coordinator and where legally necessary, a non-disclosure agreement for the Project (hereafter "NDA") with External Registry Partners, in order to protect Confidential Information disclosed by any of the Beneficiaries to such External Registry Partner. The NDA for External Registry Partners is enclosed in Attachment 5 and any changes thereto need to be agreed by the Beneficiaries. Such NDA shall where necessary be concluded before any confidential information beyond public information from published manuscripts and the Granting authority () will be exchanged. The Coordinator may conclude the signature of the Accession Form (Annex D) of the Regulatory Document (Appendix 4 to the Consortium Agreement) in its role of coordinator with External Registry Partners agreed upon by the Consortium Council and as described in the Grant Agreement, DoA, Part B, Section 3.3.1. The Coordinator is granted approval by the Beneficiaries to share the Regulatory Document (Appendix 4 to the Consortium Agreement) and the STOPSTORM Registry Protocol and information on any amendments of those with the External Registry Partners in order to conclude the signature of the Accession Form (Annex D) of the Regulatory Document (Appendix 4 to the Consortium Agreement). The Coordinator will inform the Beneficiaries of any non-disclosure-agreements and/or any signatures of the Accession Form (Annex D) of the Regulatory Document (Appendix 4 to the Consortium Agreement) concluded with External Registry Partners at the following Consortium Counsil meeting.

The following External Registry Partners have signed the Accession Form (Annex D) of the Regulatory Document (Appendix 4 to the Consortium Agreement) as of 2023/12/31:

UNIVERSITY OF GDANSK, established in M.Sklodowskiej-Curie 3a, 80-210 Gdansk, Poland, VAT number: 5840203593, (participation as of 2023/12/21)

MEDIZINISCHE HOCHSCHULE HANNOVER (MHH), established in Carl-Neuuberg-Straße 1, 30625 Hannover, Germany, VAT number:DE115650503, (participation as of 2023/12/11)

KLINIK DER LUDWIG-MAXIMILIAN-UNIVERSITÄT MÜNCHEN (KLINIKUM DER UNIVERSITÄT MÜNCHEN), ANSTALT DES ÖFFENTLICHEN RECHTS (LMU), Marchioninistraße 15, 81377 München, Germany, VAT number: DE813536017, (participation as of 2023/12/20)

CENTRE LEON BERARD, 28 rue Laennec 69008 LYON, France, VAT number: FR06779924133, (participation as of 2023/01/10)

KLINIKUM CHEMNITZ GGMBH, Flemmingstraße 2, 09116 Chemnitz, Germany, VAT number: DE160104141, (participation as of 2023/06/02)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Av. De Córdoba, s/n, 28041 Madrid, Spain, VAT number: ESG83727016, (participation as of 2022/10/06)

Others may follow accordingly.

4. Amendment to Section 7.3.3

Section 7.3.3 shall be amended as follows, to clarify the agreed upon procedure for budget release for subject inclusion into the STOPSTORM registry (WP3 of the Grant Agreement):

7.3.3 Reimbursement for patient enrolment

Each Beneficiary which enrols subjects to the prospective cohort study of the STOPSTORM Registry has been granted a budget for tasks 3.2 and 3.3 from the Granting Authority under the Grant Agreement for including a predefined number of subjects into the prospective cohort (DoA Part A, 1.3 WP3 and part B, Section 1.3.7). The Coordinator will withhold budget for task 3.2 and 3.3 dedicated for subject inclusion from the Beneficiaries until the final data of each subject (mandatory requirements described in DoA Part B table 1.3) has been collected and checked for quality by the Credentialing and Audit Committee as described in the Grant Agreement DoA, part B, Section 1.3.7 (Table 1.3 and Quality Assessment and Harmonisation) and as updated by the Management Board during the course of the Project (herein referred to as "Quality Check"). Once the Quality Check for each subject has been concluded, the Coordinator will release up to EURO 10.000,- (ten thousand euro) budget per subject (plus 25% indirect costs) based on actual, eligible, and auditable direct costs as mentioned in the Grant Agreement Article 6 and Chapters 4-6.

The budget release of up to EURO 10.000,- (ten thousand euro) will be split into up to EURO 7.500,- (seven thousand five hundred euro) for treatment related data and up to EURO 2.500,- (two thousand five hundred euro) for follow-up data. If two or more beneficiaries are involved with a single subject treatment that underwent the Quality Check, the budget release of up to EURO 10.000,- (ten thousand euro) will be split between those beneficiaries according to the granted budget for tasks 3.2. and 3.3. Every Beneficiary is responsible for their own financial reporting to the EC for this budget and will submit its reporting directly to the EC through the relevant portal. After approval of the reporting by the EC, the Coordinator will transfer the released budget as mentioned above to the Beneficiaries concerned. An interim payment from Coordinator to Beneficiary will not be done if the amount already paid exceeds 85% of the maximum EU contribution minus withheld subject inclusion budget for that Beneficiary until the final reporting has been approved by the EC.

In case a Beneficiary or a group of Beneficiaries will likely add less subjects to the STOPSTORM registry with concluded Quality Check than initially agreed upon based on the already included number of subjects with Quality Check concluded added by the Beneficiaries' registration rare until the end of the study recruitment (see Table 1), the budget of the Beneficiaries for task 3.2. and 3.3. concerning subject inclusion may be reallocated to other Beneficiaries or a group of Beneficiaries that included more subjects to the STOPSTORM registry with concluded Quality Checks than initially agreed upon. The budget reallocation requires the approval of the Consortium Council and subject inclusion numbers per Beneficiary or group of Beneficiaries will be determined 6 (six) weeks before a Consortium Council meeting.

Table 1: Expected inclusion rates for every participating centre in STOPSTORM as base for budget calculation in the STOPSTORM Grant Agreement

Centre	Expected inclusion in STOPSTORM registry	Registration rate per 6 months
UMCU	10	1- 2
FNO/IKEM/NPO	10	1- 2
CAU(UKSH)	~~8~~18	1
UHEI	10	1- 2
CHARITE	10	1- 2
UKD(TUD)~~/ULEIHC~~	~~1~~910	3
CHUV	6	1
BERN	6	1
USZ	6	1

NRIO/GCM	**19**	**3**
IMIM	**5**	**1**
SERMAS	**10**	**1- 2**
FIHGUV	**10**	**1- 2**
AUSL-RE	**10**	**1- 2**
IRCCSDC	**6**	**1**
UNITO	**6**	**1**
IRCCS OSM/CNAO	**6**	**1**
AH/AUH	**6**	**1**
LUMC	**19**	**3**
UMC	**6**	**1**
MAASTRO/MUMC	**19**	**3**
~~**SZC**~~	~~**10**~~	~~**1-2**~~
Total	~~**217**~~**208**	

5. Miscellaneous

5.1 All other provisions of the Consortium Agreement remain unaffected.

Attachment 1 shall apply as in the attached version.

Attachment 2 shall apply as in the attached version.

Attachment 3 shall apply as in the attached version.

Attachment 4 shall apply as in the attached version and has been amended to the changes of the Coordinator CAU and the STOPSTORM database, which will remain with UMCU.

Attachment 5 is newly included in the CA and shall apply as in the attached version.

5.2 This Amendment, forming an integral part of the Consortium Agreement, enters into force on the day of the last signature.

5.3 All references to “Coordinator” in the Consortium Agreement will refer to CAU as of 2024/01/01. However, in art. 10.8 of the Consortium Agreement the reference to “Coordinator” will refer to UMC Utrecht.

Partner 1:
CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL

Name: [redacted]
Title: Head of Research Affairs

Date: 18.09.2024

Signature: [redacted]

Organisation stamp (in blue):

[redacted]

Partner 2:
FAKULTNI NEMOCNICE OSTRAVA (FNO)

Name(s): [redacted]
Title: Director

Date:

Signature: [redacted]

Organisation stamp (in blue): [redacted]

Partner 3:
INSTITUT KLINCKÉ A EXPERIMENTÁLNÍ MEDICINY (IKEM)

Name: Ing. Helena Rögnerová
Title: Director

Date: 12. 09. 2024

Signature: [redacted]

Organisation stamp [redacted]

Partner 4:
NEMOCNICE PODLESI A.S. (NPO)

Name: [redacted]
Title: MUDr.

Date:

Signature:

Name: [redacted]
Title: Ing.

Date:

Signature [redacted]

Organisation stamp (in blue):

[redacted]

Partner 5: **UNIVERSITAIR MEDISCH CENTRUM UTRECHT (UMCU)**

Name: [redacted]
Title: Dean and Vice-chair Executive Board UMC Utrecht

Date: 11-09-2024

Signature: [redacted]

Organisation stamp (in blue):

Partner 6:

RUPRECHT-KARLS-UNIVERSITY HEIDELBERG (UHEI)

Name: [redacted]

Title: Head of Department Legal issues of Research Funding / EU Research Officer

Date: 07.09.2024

Signature [redacted]

Organisation stamp (in blue): [redacted]

Partner 7:

CHARITE - UNIVERSITAETSMEDIZIN BERLIN (CHARITE)

Name: [redacted]

Title: Faculty Business Director

Date:

Signature: [redacted]

Organisation stamp (in blue):

Partner 8:
TECHNISCHE UNIVERSITAET DRESDEN (TUD)

Name: [redacted]
Title: Head of Unit

Date: [redacted]

Signature: [redacted]

Organisation stamp (in blue):

Partner 9:

UNIVERSITAET ZU LUEBECK (UZL)

Name [redacted]

Title: President in charge

Date:

[redacted]

Organisation stamp (in blue):

[redacted]

Partner 10: n.a.

Partner 11:
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)

Name: [redacted]
Title: General Director

Date: 11. 09. 2024

Signature: [redacted]

Organisation stamp: [redacted]

Partner 12:

INSEL GRUPPE AG (BERN)

Name: [redacted]

Title: Director of Teaching and Research ~~a.i.~~

Date: 17.09.2024

Signature: [redacted]

Name: [redacted] [redacted]

Title: Attending physician Head of Radiation Oncology

Date: 19.09.2024 17.09.2024

Signature: [redacted] [redacted]

Name [redacted]

Title: Head of Cardiac Electrophysiology

Date: 17.09.2024

Signature: [redacted]

Organisation stamp (in blue):

[redacted]

Partner 13:
UNIVERSITÄT ZÜRICH (UZH)

Name: [redacted]
Title: Vice President Research

Date: 19/3/2024

Signature: [redacted]

Organisation stamp (in blue): [redacted]

Partner 14:

NARODOWY INSTYTUT ONKOLOGII IM. MARII SKŁODOWSKIEJ-CURIE – PAŃSTWOWY INSTYTUT BADAWCZY (NRIO)

Name: [redacted]

Title: Deputy Director for Scientific Matters

Date: 10/09/2024

Signature: [redacted]

Organisation stamp (in blue): [redacted]

Partner 15:

GORNOSLASKIE CENTRUM MEDYCZNE IM. PROF. LESZKA GIECA SLASKIEGO UNIWERSYTETU MEDYCZNEGO W KATOWICACH (GCM)

Name: [redacted]

Title: Director

Date:

Signature:

Organisation stamp (in blue): [redacted]

27.09.2024 r.

[redacted]

Partner 16:
AARHUS UNIVERSITET (AU)

Name: [redacted]
Title: Head of AU Technology Transfer Office

Date:

Signature: [redacted]

Organisation stamp (in blue):

Partner 17:

AARHUS UNIVERSITETSHOSPITAL (AUH)

Name: [redacted]

Title: CISO, Region Midtjylland

Date:

Signature: [redacted]

Organisation stamp (in blue):

Partner 18:

CONSORCIO MAR PARC DE SALUT DE BARCELONA (IMIM)

Name: [redacted]

Title: Manager

Date:

Signature: [redacted]

Organisation stamp (in blue):

Partner 19:

SERVICIO MADRILEÑO DE SALUD (SERMAS)

Name: [redacted]

Title: General Director HCSC/SERMAS

Date:

Sign

Orga

[redacted]

Partner 20:

FUNDACION INVESTIGACIÓN HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA (FIHGUV)

Name: [redacted]

Title: Manager FIHGUV

CIF: G96792221

Firmado por ***3639* [redacted] :****9222*) el día 12/09/2024 con un certificado emitido por ACCVCA-120

Date:

Signature:

Organisation stamp (in blue):

[redacted]

Partner 21:

AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA (AUSL-RE)

Name: [redacted]

Title: Scientific Director of Azienda Unità Sanitaria Locale-IRCCS in Reggio Emilia

Date: SEPTEMBER 12, 2024

Signature:

[redacted]

Organisation stamp (in blue):

[redacted]

Partner 22:

FONDAZIONE CENTRO NAZIONALE DI ADROTERAPIA ONCOLOGICA (CNAO)

Name: [redacted]

Title: President

Date: 16/09/2024

Signature: [redacted]

Organisation stamp (if due): [redacted]

Partner 23:

ISTITUTO DON CALABRIA – IRCCS OSPEDALE SACRO CUORE DON CALABRIA (IRCCSDC)

Name: [redacted]

Title: Legal Representative

Date:

Signature [redacted]

Organisation stamp (in blue):

Partner 24

UNIVERSITA DEGLI STUDI DI TORINO (UNITO)

Name: [redacted]

Title: Director of Department of Medical Sciences

Date: 03/05/2

Signature: [redacted]

Organisation stamp (in blue):

Partner 25:

FONDAZIONE IRCCS POLICLINICO SAN MATTEO (IRCCS OSM)

Name: [redacted]

Title: Scientific Director

Date: 06/09/2024

Signature: [redacted]

Organisation stamp (in [redacted]

Partner 26:
UNIVERSITEIT MAASTRICHT (UM)

Name: [redacted]
Title: Scientific director CARIM

Date: 06-09-2024

Signature: [redacted]

Organisat[redacted]

Partner 27:

ACADEMISCH ZIEKENHUIS LEIDEN (LUMC)

Name: [redacted]

Title: Managing Director Division 4 LUMC

Date: 19/09/2024

Signature:

[redacted]

Organisation stamp (in blue):

[redacted]

Partner 28:
STICHTING AMSTERDAM (UMC
Name: [redacted]
Title: Chairman of the Executive

Date: 10-10-2024

Signature: [redacted]

Organisation stamp (in blue):

Read and acknowledged by: AMC Principal Investigator

Name: [redacted]

[redacted]

Partner 29:

STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC (MAASTRO)

Name: [redacted]

Title: CEO

Date: 12 september 2024 | 22:12 PDT

Signature: [redacted]

Organisation stamp (in blue):

Partner 30: n.a.

Partner 31:
HARTERAAD (HART)

Name: [redacted]
Title: Director ad interim

Date: 12-9-24

[redacted]

Harteraad
voor mensen
met hart- en
vaataandoeningen

Attachment 1: Background included

According to the Grant Agreement (Article 24) Background is defined as "data, know-how or information (…) that is needed to implement the action or exploit the results". Because of this need, Access Rights have to be granted in principle, but Beneficiaries must identify and agree amongst them on the Background for the project. This is the purpose of this attachment.

BENEFICIARY 1

As to **CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL (CAU)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for Exploitation (Article 25.3 Grant Agreement)
Site specific treated patients and their data collected within the German RAVENTA trial (NCT03867747) before RAVENTA is adapted to the prospective STOPStorm project as described in WP3 will be added to the retrospective patient database in the STOPStorm project as described in WP1	For site specific patient data within the RAVENTA trial there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for data sharing within the RAVENTA trial OR 2) the patient data is submitted anonymously into the STOPStorm database	The data will be used for publications as defined in the RAVENTA trial protocol and for further inhouse developments and subsequent publications if desired.
Individually treated patients under compassionate use and their data collected will be added to the retrospective patient database in the STOPStorm project as described in WP1	For individual patient data there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for individual data sharing OR 2) the patient data is submitted anonymously into the STOPStorm database	The data will be used for further inhouse developments and subsequent publications if desired.

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 2

As to **FAKULTNI NEMOCNICE OSTRAVA (FNO)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **FAKULTNI NEMOCNICE OSTRAVA (FNO)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 3

As to **INSTITUT KLINCKÉ A EXPERIMENTÁLNÍ MEDICINY (IKEM)**, it is agreed between the Beneficiaries that, to the best of their knowledge

No data, know-how or information of **INSTITUT KLINCKÉ A EXPERIMENTÁLNÍ MEDICINY (IKEM)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 4

As to **NEMOCNICE PODLESI A.S. (NPO)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **NEMOCNICE PODLESI A.S. (NPO)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 5

As to **UNIVERSITAIR MEDISCH CENTRUM UTRECHT (UMCU)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **UNIVERSITAIR MEDISCH CENTRUM UTRECHT (UMCU)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 6

As to **RUPRECHT-KARLS-UNIVERSITY HEIDELBERG (UHEI)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for Exploitation (Article 25.3 Grant Agreement)
Site specific treated patients and their data collected within the German RAVENTA trial (NCT03867747) before RAVENTA is adapted to the prospective STOPSTORM project as described in WP3 will be added to the retrospective patient database in the STOPSTORM project as described in WP2	For site specific patient data within the RAVENTA trial there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for data sharing within the RAVENTA trial OR 2) the patient data is submitted anonymously into the STOPSTORM database	The data will be used for publications as defined in the RAVENTA trial protocol and for further inhouse developments and subsequent publications if desired.
Individually treated patients under compassionate use and their data collected will be added to the retrospective patient database in the STOPSTORM project as described in WP2	For individual patient data there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for individual data sharing OR 2) the patient data is submitted anonymously into the STOPSTORM database	The data will be used for further inhouse developments and subsequent publications if desired.

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 7

As to **CHARITE - UNIVERSITAETSMEDIZIN BERLIN (CHARITE)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **CHARITE - UNIVERSITAETSMEDIZIN BERLIN (CHARITE)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 8

As to **TECHNISCHE UNIVERSITAET DRESDEN (TUD)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for Exploitation (Article 25.3 Grant Agreement)
Site specific treated patients and their data collected within the German RAVENTA trial (NCT03867747) before RAVENTA is adapted to the prospective STOPSTORM project as described in WP3 will be added to the retrospective patient database in the STOPSTORM project as described in the respected work package	For site specific patient data within the RAVENTA trial there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for data sharing within the RAVENTA trial OR 2) the patient data is submitted anonymously into the STOPSTORM database	The data will be used for publications as defined in the RAVENTA trial protocol and for further inhouse developments and subsequent publications if desired.
Individually treated patients under compassionate use and their data collected will be added to the retrospective patient database in the STOPSTORM project as described in the respected work package.	For individual patient data there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for individual data sharing OR 2) the patient data is submitted anonymously into the STOPSTORM database	The data will be used for further inhouse developments and subsequent publications if desired.

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 9

As to **UNIVERSITAET ZU LUEBECK (UZL)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **UNIVERSITAET ZU LUEBECK (UZL)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

~~**BENEFICIARY 10**~~

~~As to **HERZZENTRUM LEIPZIG GMBH (ULEIHC)**, it is agreed between the Beneficiaries that, to the best of their knowledge,~~

~~No data, know-how or information of **HERZZENTRUM LEIPZIG GMBH (ULEIHC)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).~~

~~This represents the status at the time of signature of this Consortium Agreement.~~

BENEFICIARY 11

As to **CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 12

As to **INSEL GRUPPE AG (BERN)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **INSEL GRUPPE AG (BERN)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 13

As to **UNIVERSITÄTSSPITAL ZÜRICH (USZ)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **UNIVERSITÄTSSPITAL ZÜRICH (USZ)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 14

As to **NARODOWY INSTYTUT ONKOLOGII IM. MARII SKŁODOWSKIEJ-CURIE – PAŃSTWOWY INSTYTUT BADAWCZY (NRIO)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for Exploitation (Article 25.3 Grant Agreement)
Site specific treated patients and their data collected within the Polish SMART-VT trial (NCT04642963) before SMART-VT is adapted to the prospective STOPSTORM project as described in WP3 will be added to the retrospective patient database in the STOPSTROM project as described in WP1	For site specific patient data within the SMART-VT trial there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for data sharing within the SMART-VT trial OR 2) the patient data is submitted anonymously into the STOPSTORM database	The data will be used for publications as defined in the SMART-VT trial protocol and for further inhouse developments and subsequent publications if desired.
Individually treated patients under compassionate use and their data collected will be added to the retrospective patient database in the STOPSTORM project as described in WP1	For individual patient data there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for individual data sharing OR 2) the patient data is submitted anonymously into the STOPSTORM database	The data will be used for further inhouse developments and subsequent publications if desired

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 15

As to **GORNOSLASKIE CENTRUM MEDYCZNE IM. PROF. LESZKA GIECA SLASKIEGO UNIWERSYTETU MEDYCZNEGO W KATOWICACH (GCM)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **GORNOSLASKIE CENTRUM MEDYCZNE IM. PROF. LESZKA GIECA SLASKIEGO UNIWERSYTETU MEDYCZNEGO W KATOWICACH (GCM)**

shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 16

As to **AARHUS UNIVERSITET (AU)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **AARHUS UNIVERSITET (AU)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 17

As to **AARHUS UNIVERSITETSHOSPITAL (AUH)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for Exploitation (Article 25.3 Grant Agreement)
At Aarhus University Hospital an atlas based method for autosegmentation of substructures in the heart has been developed. It will be optimised to STOPSTORM patients within in current project.		

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 18

As to **CONSORCIO MAR PARC DE SALUT DE BARCELONA (IMIM)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **CONSORCIO MAR PARC DE SALUT DE BARCELONA (IMIM)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 19

As to **SERVICIO MADRILEÑO DE SALUD (SERMAS)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **SERVICIO MADRILEÑO DE SALUD (SERMAS)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 20

As to **FUNDACION INVESTIGACIÓN HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA (FIHGUV)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for Exploitation (Article 25.3 Grant Agreement)
Site specific treated patients and their data collected within the Spanish RANIT trial before RANIT is adapted to the prospective STOPStorm project as described in WP3 will be added to the retrospective patient database in the STOPStorm project as described in WP1	For site specific patient data within the RANIT trial there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for data sharing within the RANIT trial OR 2) the patient data is submitted anonymously into the STOPStorm database	The data will be used for publications as defined in the RANIT trial protocol and for further inhouse developments and subsequent publications if desired.
Individually treated patients under compassionate use and their data collected will be added to the retrospective patient database in the	For individual patient data there is no limitation for implementation under one of the following conditions:	The data will be used for further inhouse developments and subsequent publications if desired.

STOPStorm project as described in WP1	1) the patient has not withdrawn his consent for individual data sharing OR 2) the patient data is submitted anonymously into the STOPStorm database	

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 21

As to **AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA (AUSL-RE)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA (AUSL-RE)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 22

As to **FONDAZIONE CENTRO NAZIONALE DI ADROTERAPIA ONCOLOGICA (CNAO)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **FONDAZIONE CENTRO NAZIONALE DI ADROTERAPIA ONCOLOGICA (CNAO)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 23

As to **IRCCS SACRO CUORE DON CALABRIA (IRCCSDC)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **IRCCS SACRO CUORE DON CALABRIA (IRCCSDC)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 24

As to **UNIVERSITA DEGLI STUDI DI TORINO (UNITO)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **UNIVERSITA DEGLI STUDI DI TORINO (UNITO)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 25

As to **FONDAZIONE IRCCS POLICLINICO SAN MATTEO (IRCCS OSM)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **FONDAZIONE IRCCS POLICLINICO SAN MATTEO (IRCCS OSM)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 26

As to **UNIVERSITEIT MAASTRICHT (UM)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **UNIVERSITEIT MAASTRICHT (UM)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 27

As to **ACADEMISCH ZIEKENHUIS LEIDEN (LUMC)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Site specific treated patients and their data collected within the Dutch START trial(s) before START is adapted to the prospective STOPSTORM project as described in WP3 will be added to the retrospective patient database in the STOPSTORM project as described in WP1	For site specific patient data within the START trial(s) there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for data sharing within the START trial OR 2) the patient data is submitted anonymously into the STOPSTORM database	Publication of this data is subject to the terms of the START trial protocol. The use of the data is only permitted for the Implementation of this consortium agreement and publication within this consortium. The use of the data outside this scope is not allowed. No duplication/ reproduction/ downloading rights.
Individually treated patients under compassionate use and their data collected will be added to the retrospective patient database in the STOPSTORM project as described in WP1	For individual patient data there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for individual data sharing OR 2) the patient data is submitted anonymously into the STOPSTORM database	Publication of this data is subject to the terms of the START trial protocol. The use of the data is only permitted for the Implementation of this consortium agreement and publication within this consortium. The use of the data outside this scope is not allowed. No duplication/ reproduction/ downloading rights.

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 28

As to **STICHTING AMSTERDAM (UMC)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

The following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for Exploitation (Article 25.3 Grant Agreement)
Site specific treated patients and their data collected within the Dutch STARNL trial(s)	For site specific patient data within the STARNL trial(s) there is no limitation	Use of the data is limited to further research and inhouse developments and subject to

before STARNL is adapted to the prospective STOPSTORM project as described in WP3 will be added to the retrospective patient database in the STOPSTORM project as described in WP1	for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for data sharing within the STARNL trial OR 2) the patient data is submitted anonymously into the STOPSTORM database Publication of this data is subject to the terms of the STARNL trial protocol	the terms of the STARNL trial protocol, Consortium Agreement and Registry Document
Individually treated patients under compassionate use and their data collected will be added to the retrospective patient database in the STOPSTORM project as described in WP1	For individual patient data there is no limitation for implementation under one of the following conditions: 1) the patient has not withdrawn his consent for individual data sharing OR 2) the patient data is submitted anonymously into the STOPSTORM database	Use of the data is limited to further research and inhouse developments and subject to the terms of the Consortium Agreement and Registry Document

This represents the status at the time of signature of this Consortium Agreement.

BENEFICIARY 29

As to **STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC (MAASTRO)**, it is agreed between the Beneficiaries that, to the best of their knowledge,

No data, know-how or information of **STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC (MAASTRO)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

~~**BENEFICIARY 30**~~

~~As to **STICHTING CATHARINA ZIEKENHUIS (SCZ)**, it is agreed between the Beneficiaries that, to the best of their knowledge,~~

~~No data, know-how or information of **STICHTING CATHARINA ZIEKENHUIS (SCZ)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).~~

~~This represents the status at the time of signature of this Consortium Agreement.~~

BENEFICIARY 31

As to **HARTERAAD (HART)**, it is agreed between the Beneficiaries that, to the best of their knowledge

No data, know-how or information of **HARTERAAD (HART)** shall be Needed by another Beneficiary for implementation of the Project (Article 25.2 Grant Agreement) or Exploitation of that other Beneficiary's Results (Article 25.3 Grant Agreement).

This represents the status at the time of signature of this Consortium Agreement.

Attachment 2: Accession document

ACCESSION

of a new Party to

[Acronym of the Project] Consortium Agreement, version [..., YYYY-MM-DD]

[OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE Grant Agreement]

hereby consents to become a Party to the Consortium Agreement identified above as Beneficiary and accepts all the rights and obligations of a Party starting [date].

[OFFICIAL NAME OF THE COORDINATOR AS IDENTIFIED IN THE Grant Agreement]

hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new Party] to the consortium starting [date].

This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives.

[Date and Place]

[INSERT NAME OF THE NEW PARTY]
Signature(s)
Name(s)
Title(s)

[Date and Place]

[INSERT NAME OF THE COORDINATOR]
Signature(s)
Name(s)
Title(s)

Attachment 3: List of Third Parties for simplified transfer according to Section 8.3.2.

Partner 1 CAU: Universitätsklinikum Schleswig-Holstein (UKSH)

Partner 8 TUD: Universitätsklinikum Carl Gustav Carus Dresden (UKD)

Partner 9 UZL: Universitätsklinikum Schleswig-Holstein (UKSH)

Partner 18 IMIM: Fundació Institut Hospital del Mar d'Investigacions Mèdiques (FIMIM)

Partner 19 SERMAS: Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (FIB HCSC)

Partner 26 UM: Academisch Ziekenhuis Maastricht (azM/MUMC)

Attachment 4: Registry Regulatory Document

Due to changes within the Project and the responsibility assignment, the Regulatory Document was amended.

The STOPSTORM Registry database is hosted, maintained, and administrated by the Universitair Medisch Centrum Utrecht – named as Database Center.

The Registry Regulatory Document is attached in a separate Document with its track changed version: Regulatory Document – STOPSTORM – v2.1, 24 Apr 2024